[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593034":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":14,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de la Guadeloupe","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"RA-Group",null,"When a sickle cell patient comes to the emergency department with pain such as vaso-occlusive crises, we will offer them the opportunity to participate in the study. Inclusion will therefore occur before the choice of analgesic technique. The patient will receive the treatment they have chosen (with or without regional anesthesia). Depending on their choice and\u002For any contraindications (e.g., morphine intolerance or allergy to ropivacaine), they will be placed in the \"RA group\" (if they received regional anesthesia) or the \"non-RA group\" (if they did not receive it).",{"label":13,"type":10,"description":11,"interventionNames":10},"Non-RA group",[15],{"name":16,"affiliation":17,"role":18},"Amelie Rolle, MD","CHU de la Guadeloupe","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Valérie Hamony Soter","CONTACT","+590590934677","valerie.soter@chu-guadeloupe.fr",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Mélanie Petapermal","+590590934667","melanie.petapermal@chu-guadeloupe.fr",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":10,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Chu de La Guadeloupe","RECRUITING","Pointe-à-Pitre","97159","Guadeloupe",{"type":37,"coordinates":38},"Point",[39,40],-61.53459,16.23638,{"lat":40,"lon":39},[43,45],{"name":44,"role":22,"phone":27,"phoneExt":10,"email":28},"Mélanie petapermal",{"name":16,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100593034","impact-of-regional-anesthesia-on-inflammatory-mechanisms-during-vaso-occlusive-crisis-in-sickle-cell-patients-100593034",false,"NCT07001189","Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients","ALRCVO-MP","Inclusion Criteria:\n\n* patients adult \\>18 years\n* patients with vaso-occlusive crisis\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Blood transfusion within the last 3 months\n* Lack of affiliation with the French social security system\n* Protected individuals","ALL","18 Years",{"count":58,"type":59},34,"ESTIMATED","OBSERVATIONAL","Sickle cell disease is a chronic disease characterized by multiple vaso-occlusive complications. The basic treatment for patients with a vaso-occlusive crisis (VOC) is based on adequate hydration, oxygen therapy and pain control. Loco Regional Anesthesia (LRA) is one of the major treatments in resuscitation anesthesia for both anesthesia and analgesia. LRA allows effective and almost immediate pain control by blocking nerve afferents in a given area. LRA could decrease the inflammatory response during crises and accelerate resolution of the crisis.",[63,64,65],"Sickle Cell","Sickle Cell Disease","Vaso-Occlusive Crises",[67,68,65],"Loco-regional anesthesia","inflammation","2025-05-23",{"date":71,"type":72},"2025-06-03","ACTUAL",{"date":74,"type":72},"2025-02-05",{"date":76,"type":59},"2027-02-05",{"name":5,"class":6},1]